Watch again our Webinar on “Left Main PCI and Bifurcations: LATAM Bif Registry” on our Youtube account. The event was held on March 3rd, 2021, and had the participation of almost 700 people and the support of ABBOTT, Boston Scientific, Medtronic and Terumo. Webinar Contents 00:02 | Introduction – Dr. José Mangione (BRA). 04:58 |...
03/03 | SOLACI Webinar – Left Main PCI and Bifurcations: LATAM Bif Registry
We invite you to participate in the first free SOLACI virtual event of 2021. It is carried out with the support of Abbott, Boston Scientific, Medtronic and Terumo Interventional Systems and will have the participation of prestigious hemodynamicists from Latin America and the world. The title of the event is: “Left Main PCI and Bifurcations:...
The Transradial Approach Continues to Be the Best for Primary PCI
The transradial approach has been associated to lower mortality and bleeding rates in patients receiving primary PCI for ST elevation MI. This had been called into question by the recent SAFARI-STEMI, but after including its outcomes in a new meta-analysis, the scales tilted slightly in favor of the transradial approach vs. the transfemoral. The transradial...
Dual Layered for Dual Protection in Carotid PCI
At present, there is more than one dual layered stent in the market offering additional protection in carotid PCI. Therefore we saw fit to look at these devices to compare class benefits and find any specific differences. This study assessed the safety and efficacy of two dual layered mesh covered stents especially designed for carotid...
TCT 2020 | New Information about Pre and Post PCI FFR Value
The TARGET FFR and DEFINE-FLOW studies were presented at TCT 2020 which have offer a deeper perspective on the value of FFR, not only before but also after PCI. TARGET FFR The TARGET FFR included 260 patients randomized after angiographically successful PCI to an FFR guided optimization vs. blinded FFR assessment strategies. In the guided...
TCT 2020 | Crushed Prasugrel Administration prior PCI
Prehospital administration of crushed tablets of prasugrel loading dose in the ambulance while patient is on his way to primary PCI does not improve reperfusion markers compared against uncrushed tablet administration according to the COMPARE CRUSH, presented at the virtual TCT 2020 and simultaneously published in Circulation. There were no differences in TIMI flow of...
Complex PCI: Complex Characteristics Impact Results
Patients with a bigger number of complex anatomical characteristics that increase PCI complexity have worse results at one-year followup. These data come from a large multicenter study (e-Ultimaster) recently published in EuroIntervention. The more complex the characteristics, the greater the increase in events. It is important to see past the obvious anatomical challenges (bifurcations, calcification,...
ESC 2020 | Post PCI Trimetazidine: No Adverse Events or Great Benefits
Trimetazidine in addition to optimal medical therapy in patients undergoing coronary PCI does not change events rate at long term. The ATPCI study was presented at ESC 2020 and simultaneously published in the Lancet. This study randomized coronary PCI patients with stable or acute NSTEMI coronary syndromes to trimetazidine vs. placebo. What is the rationale...
SOLACI PERIPHERAL | 3rd Clinical Case: Femoral PCI
In keeping with its Clinical Case Discussion Program, SOLACI’s peripheral interventions department, SOLACI Peripheral, presents the third clinical case, to promote knowledge exchange across the entire Latin American hemodynamics community. Share your thoughts on case and resolution in the comments and answer the questions at the end of the article. Femoral PCI Authors: MD Mauricio Cavalieri...
Ideal Area for Unprotected Left Main PCI
Courtesy of Dr. Carlos Fava. Unprotected left main PCI (PCI-UPLMS) is an acceptable and comparable strategy vs CABG, although the use of IVUS is advisable, since it has shown better evolution and mortality. However, the adequate stent expansion remains unclear. Researchers carried out a sub-analyzis of the NOBLE trial. Of the total 603 patients receiving...